Daniel Chan

Dr. Daniel Chan is a distinguished scientist and academician, currently serving as a Professor of Molecular Pathology and the Director of the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine in Baltimore, Maryland, USA. He holds a joint appointment in the Department of Oncology and Department of Pathology. Dr. Chan is also a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Chan has made significant contributions to the field of cancer biomarker research, with a primary focus on the discovery, development, and clinical application of novel protein biomarkers for early cancer detection, diagnosis, prognosis, and prediction of treatment response. His research has led to the development of several FDA-approved clinical tests, including the OVA1 test for ovarian cancer, the Prostate Health Index (phi) for prostate cancer, and the EarlyCDT-Lung test for lung cancer.    In recognition of his substantial accomplishments, Dr. Chan has received several prestigious awards and honors, including the American Association for Clinical Chemistry's (AACC) Outstanding Contributions to Clinical Chemistry in a Selected Area of Research Award, the Clinical Ligand Assay Society's Dr. Bernard G. Greenberg Scientific Achievement Award, and the Johns Hopkins University School of Medicine's Distinguished Alumni Award.   Dr. Daniel Chan's unwavering dedication to advancing the field of molecular pathology and biomarker research has led to the development of groundbreaking diagnostic tools that have significantly improved the lives of cancer patients worldwide. His continued efforts in this domain promise to further revolutionize cancer detection, treatment, and management.